Date
20 November 2017

Drugmaker Actavis to quit China, Bloomberg says

Actavis Plc, the second-biggest generic drugmaker by market capitalization, will pull out of China because of the difficult business climate, Bloomberg reported Thursday, citing Actavis chief executive officer Paul Bisaro. Bisaro said the government has made it a difficult place to do business. Actavis hasn’t faced any accusations of corruption but Bisaro said he isn’t confident the company would get a fair hearing if such claims arose, the report said.

– Contact HKEJ [email protected]

SK

EJI Weekly Newsletter

Please click here to unsubscribe